An interventional study of High-flux hemodialysis and Hemodiafiltration in Hemodialysis, Hemodiafiltration and Fatigue Symptom, sponsored by AUB Santé. Recruiting at 4 sites in France. Open to participants aged 85 Years and older. Per ClinicalTrials.gov, last updated 2026-02-23.
Sponsored by AUB Santé · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 105 studies in Fatigue with a site in France — 34 open to participants now, 37 under way, 4 of them phase 3. Fatigue · France.
Among the 105 studies in Fatigue with a site in France, this one is the 39th largest by planned enrollment of the 73 interventional ones that give a count, is one of 8 that started in 2026, is one of 61 with no phase, reaches primary completion later than 20 of the 36 other live ones, and was the 96th registered.
2,234 studies on the registry are indexed under Fatigue; 430 are open to participants now.
Browse Fatigue studies →34 of the 105 studies in Fatigue with a site in France are open now. Recruiting first, the newest first:
Centre Antoine Lacassagne · Sites in France
Ages 18–75
Novartis Pharmaceuticals · Sites in France, United States, Australia and 17 more countries
Ages 18+
Harmony Biosciences Management, Inc. · Sites in France, United States, Belgium and 4 more countries
Ages 18+
Centre Medical ISM (Integrative Systemic Medicine) · Sites in France
Ages 18+
Alkermes, Inc. · Sites in France, United States, Australia and 12 more countries
Ages 18–70
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 242 Fatigue studies recruiting now, 113 (47%) set no upper age limit and 99 (41%) stop at 75 or younger; 23 take children under 18; 74 take healthy volunteers.
This study: 85 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
105 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 6 · Phase 4 2
First in 2005; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 62 is above the median of 54 across 1,762 interventional studies indexed under Fatigue.
Median enrollment 70 across the 73 interventional studies, 60 across the 32 observational. Of the 57 that completed or were terminated, 4 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 105 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with AUB Santé as lead sponsor.
AUB Santé has 1 study filed under Fatigue — fewer than ten, so there is no comparison to draw.
10 of the studies in Fatigue with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07455383Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 | 2027-05 |
| NCT07675135Phase 3Harmony Biosciences Management, Inc.A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy | 2027-10 |
| NCT07054112University Hospital, ToursEfficacy of Live Online Course Mindfulness Program on Perceived Fatigue in Hemodialysis Patients | 2026-11-30 |
| NCT07310342University Hospital, BordeauxPhysical Fitness of Children, Adolescents and Young Adults With Immune Thrombocytopenic Purpura | 2026-12-15 |
| NCT07278973AUB SantéHemodiafiltration Versus Hemodialysis in Older People | 2026-12-19 |
Add all 10 to your calendar (.ics) → With an account.
Among the 105 studies in Fatigue with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will compare the impact of two hemodialysis techniques on fatigue and post-dialysis recovery time in patients aged 85 years and older. These two techniques are high-flux hemodialysis (HD) and hemodiafiltration (HDF).
Patients will receive the treatment over two periods: if period 1 is HD then period 2 will be HDF. Every patient will be his/her own control, this is why it is called cross-over. Each period will last three months. Between the two periods, patients will receive a traditional low-flux hemodialysis.
These two techniques are widely used worldwide and their side-effects are well-known and do not put the patients at risk. HDF has been shown to improve survival in patients with a mean age of 58 years. But a previous study from the investigators' group showed that HDF causes a prolonged recovery time in older patients. This randomized trial aims to elucidate this question.
Study purpose: To determine the best modality of hemodialysis in older patients > 84 years
Study Design: Randomized, multicenter, crossover, pragmatic clinical trial.
Eligible participants will be randomized in a 1:1 ratio for HDF or high-flux hemodialysis using a centralized, web-based randomization module integrated into the DATACAPT electronic case report form (eCRF). Allocation concealment will be ensured because the treatment assignment will only be generated after the patient has been enrolled and all eligibility criteria have been confirmed within the eCRF system.
Investigators and study personnel will not have access to the allocation sequence or block sizes prior to randomization.
Patients will be randomized to two sequences, each one of a 3-month period. Sequence 1 includes 3 months of hemodiafiltration (Period 1) then 3 months of high-flux hemodialysis (Period 2). Sequence 2 includes 3 months of high-flux hemodialysis (Period 1) then 3 months of hemodiafiltration (Period 2).
Washout period: Two weeks of low-flux hemodialysis at the beginning of the study and between the two periods of each sequence.
Blinding: the participant, investigators and outcome assessors are not blinded the intervention.
Primary objective: To compare the dialysis recovery time in older patients treated with hemodiafiltration versus conventional high-flux hemodialysis
Secondary objectives
Eligibility criteria: described under the section "Eligibility".
Duration of study for each participant: 7 months (including 2 initial weeks of washout and 2 weeks of washout between period 1 and period 2) Total duration of study: 8-10 months
Data collection at screening/randomization
Data collection at follow-up
-Laboratory measurements The investigators will collect at one month, two months and three months of Period 1 and Period 2 the routine laboratory tests: serum urea, creatinine, phosphate, calcium, albumin, potassium, sodium, bicarbonate, hemoglobin, PTH, alkaline phosphatase, ferritin, transferrin saturation.
At the end of each period, residual kidney function will be collected.
Primary and Secondary Endpoints: defined under the section "Outcome measures".
Planned number of participants: 62 patients
Statistical analysis Analyses will be performed on an intention-to-treat basis. Baseline characteristics will be compared using the independent t-test or Mann-Whitney U test for continuous variables and Chi-Square test for categorical variables. Linear mixed models will be used to compare the outcomes.
Ethics: The study will be conducted according to the principles of the Declaration of Helsinki 1975.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The patient will receive three months of HD followed by three months of HDF
Other: High-flux hemodialysis · Other: Hemodiafiltration
The patient will receive three months of HDF followed by three months of HD
Other: High-flux hemodialysis · Other: Hemodiafiltration
High-flux hemodialysis removes small and middle molecular solutes through the mechanism of diffusion.
Hemodiafiltration removes solutes using convection which allows for more epuration of middle molecular solutes.
Change in dialysis recovery time
Time in minutes that the patient needs after dialysis to recover energy
Time frame: Three months
Change in fatigue score
Fatigue will be assessed using the Standardized Outcomes in Nephrology (SONG) fatigue scale: from 0 to 9, higher meaning worse outcomes.
Time frame: Three months
Change in STS-30
The number of stand-to-sit over 30 seconds will be recorded. The higher the better outcome.
Time frame: Three months
Change in SF-12 scores
Quality of life scale (12 items), from 0 to 100, the higher the better outcome.
Time frame: Three months
Number of episodes of of symptomatic hypotension
Drop in blood pressure with symptoms
Time frame: Three months
Number of intradialytic clotting events
Time frame: Three months
Change in hemoglobin level
Time frame: Three months
Change in serum albumin
Time frame: Three months
Change in serum potassium level
Time frame: Three months
Change in serum phosphate
Time frame: Three months
Change in Kt/V
Dialysis adequacy
Time frame: Three months
Hospitalisation
Whether the patient was admitted to hospital during the study period
Time frame: From the start to the end of period 1 (HD) and from the start to the end of period 2 (HDF)
Death
Time frame: From the start to the end of period 1 (HD) and from the start to the end of period 2 (HDF)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Start is estimated for Feb 2026; primary completion for Dec 2026, 10 months later.
Of 937 non-industry interventional studies with no phase under Fatigue, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 10 months is below that.
Counting every sponsor, half of 990 studies reached it within 12 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.